title: Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients.
abstract: BACKGROUND
  This study investigates the effect of amlodipine on arterial compliance (AC), and the effect of atorvastatin on AC when given in combination with amlodipine.
  
  
  METHODS
  Twenty-one consecutive hypertensive hyperlipidemic patients were included in this study. Patients were followed every month for 6 months (3 months of amlodipine therapy and 3 months of amlodipine and atorvastatin combination).
  
  
  RESULTS
  During the 3 months of amlodipine monotherapy, large and small AC were improved by 26% and 38%, respectively, and the systemic vascular resistance was reduced by 10%. The addition of atorvastatin during the next 3 months improved small AC by an additional 42% and decreased the systemic vascular resistance by another 5%, but large AC and blood pressure did not change.
  
  
  CONCLUSIONS
  Amlodipine improves large and small AC, and the beneficial effect of atorvastatin on small AC is additive to the effect achieved by amlodipine.
authors.affiliation: Department of Medicine and the Bruner Institute of Cardiovascular Research, Wolfson Medical Center, Tel Giborim, PO Box 5, Holon, Israel 58100.
authors.forename: Eyal
authors.initials: E
authors.lastname: Leibovitz
authors.forename: Maya
authors.initials: M
authors.lastname: Beniashvili
authors.forename: Reuven
authors.initials: R
authors.lastname: Zimlichman
authors.forename: Angela
authors.initials: A
authors.lastname: Freiman
authors.forename: Marina
authors.initials: M
authors.lastname: Shargorodsky
authors.forename: Dov
authors.initials: D
authors.lastname: Gavish
mesh_terms: D000368:Aged; D017311:Amlodipine / Q000627:therapeutic use*; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001158:Arteries / Q000187:drug effects*; D000069059:Atorvastatin; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D003971:Diastole / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006339:Heart Rate / Q000187:drug effects; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000188:drug therapy*; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000627:therapeutic use*; D013318:Stroke Volume / Q000187:drug effects; D013599:Systole / Q000187:drug effects; D016896:Treatment Outcome; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D000924:Anticholesteremic Agents; D000959:Antihypertensive Agents; D015415:Biomarkers; D002121:Calcium Channel Blockers; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D017311:Amlodipine; D000069059:Atorvastatin